Evidence map›Paper›PMID 35747826›Full record

ArticleFrontiers in oncology2022

Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling.

Shuyu Wang, Dali Xu, Bo Gao, Shuhan Yan, Yiwei Sun, Xinxing Tang, Yanjia Jiao, Shan Huang, Shumei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Epigenetic and Immunological Features of Bladder Cancer.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuyu WangCollege of Information and Computer Engineering, Northeast Forestry University, Harbin, China.
Dali XuCollege of Information and Computer Engineering, Northeast Forestry University, Harbin, China.
Bo GaoDepartment of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Shuhan YanCollege of Information and Computer Engineering, Northeast Forestry University, Harbin, China.
Yiwei SunCollege of Information and Computer Engineering, Northeast Forestry University, Harbin, China.
Xinxing TangCollege of Information and Computer Engineering, Northeast Forestry University, Harbin, China.
Yanjia JiaoCollege of Information and Computer Engineering, Northeast Forestry University, Harbin, China.
Shan HuangDepartment of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Shumei ZhangCollege of Information and Computer Engineering, Northeast Forestry University, Harbin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer is a highly complex and heterogeneous malignancy. Tumor heterogeneity is a barrier to effective diagnosis and treatment of bladder cancer. Human carcinogenesis is closely related to abnormal gene expression, and DNA methylation is an important regulatory factor of gene expression. Therefore, it is of great significance for bladder cancer research to characterize tumor heterogeneity by integrating genetic and epigenetic characteristics. This study explored specific molecular subtypes based on DNA methylation status and identified subtype-specific characteristics using patient samples from the TCGA database with DNA methylation and gene expression were measured simultaneously. The results were validated using an independent cohort from GEO database. Four DNA methylation molecular subtypes of bladder cancer were obtained with different prognostic states. In addition, subtype-specific DNA methylation markers were identified using an information entropy-based algorithm to represent the unique molecular characteristics of the subtype and verified in the test set. The results of this study can provide an important reference for clinicians to make treatment decisions.

Indexed as

bladder cancerDNA methylationheterogeneity analysismolecular subtypessubtype specific biomarkers

Identifiers

PMID35747826
PMCPMC9209659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.